GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers
- Conditions
- Type 2 Diabetes MellitusDiabetes Mellitus, Type 2
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8
- Registration Number
- NCT00501683
- Locations
- πΊπΈ
GSK Investigational Site, Madison, Wisconsin, United States
A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function
- Conditions
- Type 2 Diabetes MellitusDiabetes Mellitus, Type 2Renal Insufficiency
- Interventions
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 29
- Registration Number
- NCT00501462
- Locations
- πΊπΈ
GSK Investigational Site, Austin, Texas, United States
A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder
- Conditions
- Overactive Bladder
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT00501267
- Locations
- πΊπΈ
GSK Investigational Site, Tacoma, Washington, United States
Study to Assess the Effect of Food on the Concentration of GW273225 in the Body of Healthy Male and Female Volunteers
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 14
- Registration Number
- NCT00501865
- Locations
- π¬π§
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom
Rosiglitazone on Microalbuminuria in Type 2 Diabetics
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2007-07-13
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 336
- Registration Number
- NCT00500955
- Locations
- π¬π§
GSK Investigational Site, Newport, United Kingdom
Comparison of the Efficacy and Tolerability of the Addition of AVANDIA to Submaximal Doses of Metformin
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2007-07-13
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 750
- Registration Number
- NCT00501020
Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 334
- Registration Number
- NCT00500331
- Locations
- πΏπ¦
GSK Investigational Site, Roodepoort, South Africa
A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To Healthy Males And Postmenopausal Women
- Conditions
- Osteoporosis
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2009-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT00499928
- Locations
- πΊπΈ
GSK Investigational Site, Madison, Wisconsin, United States
A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets.
- Conditions
- Schizophrenia
- Interventions
- Drug: SB- 773812 60 mgDrug: SB- 773812 120 mgDrug: Placebo
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT00500201
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Study To Examine Safety, Tolerability And Pharmacokinetics Of Intravenous Doses And Oral Dose Of GSK233705
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 9
- Registration Number
- NCT00500461
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom